Mechanism of Guishao Yigong decoction in treating colorectal cancer based on network pharmacology and experimental validation
Journal of Pharmacy and Pharmacology · 2024
DOI: 10.1093/jpp/rgae045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2024. Verfasst von Yuwen Fan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, N…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Drugs, Chinese Herbal, Antineoplastic Agents, Phytogenic. Die Arbeit nennt 61 Literaturangaben. Gefördert von: Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources.
Abstract (Originalsprache)
Objectives
To explore the effective components of Guishao Yigong decoction (GYD) in the treatment of colorectal cancer and reveal its potential mechanism of action.
Methods
Through network pharmacology, the main target and signaling pathway of GYD therapy for colorectal cancer (CRC) were found. Subsequently, the effect of GYD was verified by in vitro cell viability measurements, colony formation, and scratch healing tests. The effects of GYD on metabolic pathways in vivo were found through plasma metabolomics. Finally, flow cytometry and qPCR experiments were used to verify the cycle-blocking effect of GYD on CRC cells. Key findings Based on the network pharmacological analysis and molecular docking technology, it was found that GYD could restrain the growth of CRC cells by affecting lipid metabolic pathways and mitogen-activated protein kinase (MAPK) signaling pathways. A series of cell experiments showed that GYD could inhibit the proliferation, migration and clonogenic ability of CRC cells. Furthermore, the plasma metabolomics results showed that GYD could affect the production of unsaturated fatty acids in mice. Flow cytometry and qPCR experiments further proved that GYD blocked the CRC cells in the G1 phase and modulated the expression of cell cycle-related targets, such as AKT, TP53, CDKN1A, and CDK2.
Conclusions
All the results indicated that GYD could regulate the related metabolism of unsaturated fatty acids. Thus, the cell cycle was blocked and the expressions of the key proteins such as AKT and TP53 were regulated, which achieved the purpose of intervention in colorectal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China.
- College of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China.
Förderung
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources
Zitieren
APA
Fan, Y., Wang, Q., Zhang, Y., Wang, Y., Li, W., Jiang, S., & Duan, J. N. (2024). Mechanism of Guishao Yigong decoction in treating colorectal cancer based on network pharmacology and experimental validation. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae045
Vancouver
Fan Y, Wang Q, Zhang Y, Wang Y, Li W, Jiang S, et al. Mechanism of Guishao Yigong decoction in treating colorectal cancer based on network pharmacology and experimental validation. Journal of Pharmacy and Pharmacology. 2024. doi:10.1093/jpp/rgae045
BibTeX
@article{Fan2024,
author = {Fan, Yuwen and Wang, Quyi and Zhang, Yun and Wang, Yu and Li, Wenwen and Jiang, Shu and Duan, Ji-Nao},
title = {Mechanism of Guishao Yigong decoction in treating colorectal cancer based on network pharmacology and experimental validation},
journal = {Journal of Pharmacy and Pharmacology},
year = {2024},
doi = {10.1093/jpp/rgae045}
}
EUVIMED